• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在一项随机 III 期研究中,比较同步放化疗加辅助替莫唑胺与单纯放疗治疗胶质母细胞瘤的疗效:EORTC-NCIC 试验的 5 年分析(柳叶刀肿瘤学。2009;10:459-466)。

Commentary on Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial (Lancet Oncol. 2009;10:459-466).

机构信息

Juelich Research Center, Institute of Neurosciences and Biophysics, Juelich, Germany.

出版信息

Cancer. 2010 Apr 15;116(8):1844-6. doi: 10.1002/cncr.24950.

DOI:10.1002/cncr.24950
PMID:20151424
Abstract

Recently, un update of the important European Organization for Research and Treatment of Cancer study 26981 was published without correcting deficiencies that already were known and publicized in 2008. In the current commentary, the author specifies those issues to help prevent incorrect conclusions and discusses reasons why the journal that published the update dismissed a letter clarifying those shortcomings.

摘要

最近,一项重要的欧洲癌症研究与治疗组织研究 26981 的更新版本发布了,但没有纠正 2008 年已经发现并公布的缺陷。在当前的评论中,作者详细说明了这些问题,以帮助避免得出错误的结论,并讨论了发布更新版本的期刊为何驳回一封澄清这些缺陷的信件的原因。

相似文献

1
Commentary on Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial (Lancet Oncol. 2009;10:459-466).在一项随机 III 期研究中,比较同步放化疗加辅助替莫唑胺与单纯放疗治疗胶质母细胞瘤的疗效:EORTC-NCIC 试验的 5 年分析(柳叶刀肿瘤学。2009;10:459-466)。
Cancer. 2010 Apr 15;116(8):1844-6. doi: 10.1002/cncr.24950.
2
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.同步放化疗联合辅助替莫唑胺与单纯放疗对胶质母细胞瘤生存影响的随机III期研究:EORTC-NCIC试验的5年分析
Lancet Oncol. 2009 May;10(5):459-66. doi: 10.1016/S1470-2045(09)70025-7. Epub 2009 Mar 9.
3
Going past the data for temozolomide.略过替莫唑胺的数据。
Cancer Chemother Pharmacol. 2012 Apr;69(4):1113-5. doi: 10.1007/s00280-011-1796-4. Epub 2011 Dec 7.
4
The evolution of chemoradiation for glioblastoma: a modern success story.胶质母细胞瘤放化疗的发展:一个现代的成功案例。
Curr Oncol Rep. 2006 Jan;8(1):50-3. doi: 10.1007/s11912-006-0009-5.
5
Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial.新诊断胶质母细胞瘤的放疗与替莫唑胺治疗:EORTC 26981/22981-NCIC CE3 三期随机试验的递归划分分析
J Clin Oncol. 2006 Jun 1;24(16):2563-9. doi: 10.1200/JCO.2005.04.5963.
6
Chemotherapy for malignant gliomas.恶性胶质瘤的化疗
Wien Med Wochenschr. 2006 Jun;156(11-12):346-50. doi: 10.1007/s10354-006-0307-4.
7
Quality assurance of the EORTC 26981/22981; NCIC CE3 intergroup trial on radiotherapy with or without temozolomide for newly-diagnosed glioblastoma multiforme: the individual case review.欧洲癌症研究与治疗组织(EORTC)26981/22981试验的质量保证;加拿大国家癌症研究所(NCIC)CE3组间试验:新诊断多形性胶质母细胞瘤放疗联合或不联合替莫唑胺的个体病例回顾
Eur J Cancer. 2004 Jul;40(11):1724-30. doi: 10.1016/j.ejca.2004.03.026.
8
Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3.预测新诊断胶质母细胞瘤患者生存的列线图:欧洲癌症研究与治疗组织(EORTC)和加拿大国家癌症研究所(NCIC)试验26981-22981/CE.3的预后因素分析
Lancet Oncol. 2008 Jan;9(1):29-38. doi: 10.1016/S1470-2045(07)70384-4. Epub 2007 Dec 21.
9
Concomitant (without adjuvant) temozolomide and radiation to treat glioblastoma: a retrospective study.同步(无辅助治疗)替莫唑胺与放疗治疗胶质母细胞瘤:一项回顾性研究
Clin Oncol (R Coll Radiol). 2009 Feb;21(1):19-22. doi: 10.1016/j.clon.2008.08.008. Epub 2008 Oct 5.
10
[Temozolomide in patients with a glioblastoma multiforme: new developments].[替莫唑胺治疗多形性胶质母细胞瘤患者:新进展]
Ned Tijdschr Geneeskd. 2005 Jun 18;149(25):1376-8.

引用本文的文献

1
Spinal cord metastasis in a long-term survivor of primary malignant glioblastoma: A case report.原发性恶性胶质母细胞瘤长期存活者的脊髓转移:一例报告
Oncol Lett. 2025 May 14;30(1):343. doi: 10.3892/ol.2025.15089. eCollection 2025 Jul.
2
A 5-Year Update on the Clinical Development of Cancer Cell-Based Vaccines for Glioblastoma Multiforme.多形性胶质母细胞瘤基于癌细胞疫苗临床开发的5年进展
Pharmaceuticals (Basel). 2025 Mar 6;18(3):376. doi: 10.3390/ph18030376.
3
Identification of the high-risk population facing early death in older patients with primary intracranial glioma: a retrospective cohort study.
原发性颅内胶质瘤老年患者早期死亡高危人群的识别:一项回顾性队列研究。
Front Endocrinol (Lausanne). 2025 Mar 3;16:1546530. doi: 10.3389/fendo.2025.1546530. eCollection 2025.
4
FAM20C: A key protein kinase in multiple diseases.FAM20C:多种疾病中的关键蛋白激酶。
Genes Dis. 2023 Nov 23;12(2):101179. doi: 10.1016/j.gendis.2023.101179. eCollection 2025 Mar.
5
Identification and Verification of an Alternative Polyadenylation-Related lncRNA Prognostic Signature for Glioma.一种用于胶质瘤的替代性多聚腺苷酸化相关长链非编码RNA预后特征的鉴定与验证
Comput Math Methods Med. 2022 Sep 7;2022:2164229. doi: 10.1155/2022/2164229. eCollection 2022.
6
Prognostic relevance and validation of ARPC1A in the progression of low-grade glioma.ARPC1A 在低级别胶质瘤进展中的预后相关性和验证。
Aging (Albany NY). 2024 Jun 19;16(14):11162-11184. doi: 10.18632/aging.205952.
7
SMYD2 induced PGC1α methylation promotes stemness maintenance of glioblastoma stem cells.SMYD2 诱导 PGC1α 甲基化促进神经胶质瘤干细胞干性维持。
Neuro Oncol. 2024 Sep 5;26(9):1587-1601. doi: 10.1093/neuonc/noae090.
8
Stabilization of KPNB1 by deubiquitinase USP7 promotes glioblastoma progression through the YBX1-NLGN3 axis.去泛素化酶 USP7 通过稳定 KPNB1 促进神经胶质瘤的进展通过 YBX1-NLGN3 轴。
J Exp Clin Cancer Res. 2024 Jan 23;43(1):28. doi: 10.1186/s13046-024-02954-8.
9
EMP3 as a prognostic biomarker correlates with EMT in GBM.EMP3 作为一种预后生物标志物与 GBM 中的 EMT 相关。
BMC Cancer. 2024 Jan 17;24(1):89. doi: 10.1186/s12885-023-11796-0.
10
Ferroptosis-related gene MTF-1 as a novel prognostic biomarker in low-grade glioma and its correlation with immune infiltration.铁死亡相关基因MTF-1作为低级别胶质瘤的一种新型预后生物标志物及其与免疫浸润的相关性
Heliyon. 2023 Oct 31;9(11):e21159. doi: 10.1016/j.heliyon.2023.e21159. eCollection 2023 Nov.